glp-1 cardiovascular outcomes 2025 news Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Studies Add to Growing

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

Receptor agonist therapy offers targeted action, predictable dose responses, and potential reduction of adverse effects

The treatment is still undergoing Phase 3 clinical trials conducted by Eli Lilly, and it has not yet been submitted for regulatory approval to the Medicines and Healthcare products Regulatory Agency (MHRA)

Preclinical validation and translational planning should be emphasized in future generation or personalized scaffold solutions

GIP Receptor Agonism (Glucose-dependent Insulinotropic Polypeptide) GIP is an incretin hormone released from the gut in response to food intake